3 registrations that name astragalus as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
All 3 registrations
Not yet recruitingNCT06234072
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Phase 2
Shenzhen University General Hospital
About 120 people
Starts Feb 2024 (estimated)
In plain words A Phase 2 study of astragalus in people 18 and older, run by Shenzhen University General Hospital. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Pancreatic Cancer.
Histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma;
Is 18 years of age or older;
ECOG performance status 0 to 2;
Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times the upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastasis, then AST (SGOT) and ALT (SGPT) may be ≤ 5 times ULN.
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Astragalus + Gemcitabine; Gemcitabine alone
Registered summary
This study compare the efficacy of Astragalus combined with Gemcitabine to Gemcitabine alone as neoadjuvant treatment for pancreatic cancer.
Where, as registered
No US site; China (1).
Not yet recruitingNCT06510530
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Phase 3
Bnai Zion Medical Center
About 60 people
Starts Aug 2027 (estimated)
In plain words A Phase 3 study of astragalus in people 18 and older, run by Bnai Zion Medical Center. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: High-grade Lymphoma.
Age over 18
Diagnosis of high-grade lymphoma
Need to start treatment for lymphoma that includes chemotherapy as first line
Possibility to answer questionnaires once a month
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Astragalus; Placebo
Registered summary
Lymphoma is a malignant disease of the lymph nodes. There are different types of lymphoma: when some of the lymphomas are indolent and require only follow-up, in cases of aggressive lymphoma or indolent lymphoma with a burden of disease, treatment is necessary, which usually includes chemotherapy with or without biological drugs. The full summary is on the listing.
Where, as registered
No US site; Israel (1).
Not yet recruitingNCT07664657
To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
No phase
Sichuan Credit Pharmaceutical Co., Ltd.
About 32 people
Starts Jun 2026 (estimated)
In plain words A study of astragalus in people 18 to 45, run by Sichuan Credit Pharmaceutical Co., Ltd.. It plans to enroll about 32 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Bioavailability and Pharmacokinetics.
Participation is truly voluntarily.
Healthy adult, human Participants between 18 to 45 years of age (both inclusive) and weighing at least 50 kgs.
Having a Body Mass Index (BMI) between 18.50 and 30.00 Kg/m2 (both inclusive) calculated as weight in kg / height in m2.
Have normal clinically findings as judged by investigators during screening within 28 days prior to administration of first dose of study drug, medical history and examination, laboratory evaluations, 12-lead ECG recordings, chest X-ray…
10 more inclusion criteria and the exclusion criteria are on the listing.
An open-label, randomized, single dose study to assess dose proportionality and pharmacokinetic linearity in healthy participants under fasting condition.